FDA Approves Implantable Device to Treat RA Patients
SetPoint System, a neuroimmune modulation device, has been approved by the U.S. Food and Drug Administration to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic disease-modifying anti-rheumatic drugs.
Takeda’s New Devices for Hyqvia Infusion Can Reduce Preparation Steps By Up to One-Half
The U.S. Food and Drug Administration has granted 510(k) clearance to Takeda’s HyHub and HyHub Duo for patients 17 years of age and older that allow HYQVIA [immune globulin infusion (human), 10% with recombinant human hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting.
Myths & Facts: GLP-1 Drugs for Weight Loss
Misconceptions about GLP-1 drugs could interfere with patients’ efforts to achieve their weight-loss goals.
Diagnosing and Treating Infant Botulism
Since the approval of BabyBIG, the only treatment for this rare but life-threatening disease affecting infants mostly under 6 months, the mortality rate is now less than 15 percent.
Update on Rabies
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
New and Better Hemophilia A Treatment Options Just Keep Coming
With 16 FVIII products now approved for the treatment of hemophilia A, many patients with this disease are now able to live a normal life.
Myths & Facts: Prenatal Care
With almost a quarter of women receiving inadequate prenatal care in the U.S., more needs to be done to inform women about the myths surrounding this essential healthcare service.
New Gene Therapies Are Transformative for People with Sickle Cell Disease and Frequent Vaso-Occlusive Crises
Affecting more than 100,000 American children and adults, sickle cell disease is an inherited hemoglobinopathy that results when a single-nucleotide mutation in the ß-globin gene yields an abnormal “sickle” hemoglobin (HbS). Now, these patients may be eligible for a one-time gene therapy that offers the potential of a durable functional cure by eliminating severe VOCs and associated hospitalizations.
mRNA Cancer Therapy Boosts Immune Response
An investigational, individualized neoantigen therapy, with personalized encoded mRNA, has demonstrated potential to enable patients’ immune systems to target cells that cause cancer.
Innovations in Bioidentical Hormone Replacement Therapy
Touted as a more natural approach to hormone replacement therapy, this plant-based anti-aging remedy has evolved from an unregulated safety concern to a mainstay of modern medicine.